Immunotherapy plus chemo aims to fight bile duct cancer
NCT ID NCT04910386
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests whether adding the immunotherapy drug envafolimab to standard chemotherapy (gemcitabine plus cisplatin) helps people with advanced biliary tract cancers live longer without their cancer growing. About 126 adults who have not had prior treatment for advanced disease will be randomly assigned to receive either the combo or chemo alone. The study is open-label, meaning both doctors and patients know which treatment is given.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- envafolimab (an immunotherapy drug) plus gemcitabine and cisplatin (chemotherapy)
- What this could lead to
- If it works, this could offer a more effective first-line treatment for advanced biliary tract cancers, potentially slowing disease progression.
- What could go wrong
- This is an early Phase 2 trial with only 126 participants, so results may not be conclusive. Immunotherapy can cause immune-related side effects, and the combination may not improve outcomes over standard chemo alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A new test could reveal how radiation affects the liver
- Can blood tests reveal how liver and bile duct cancers respond to treatment?
- Can a smart drug home in on Hard-to-Treat GI cancers?
- Can matching drugs to tumor genes beat biliary cancer?
- Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
- Can a new drug ST316 shrink Hard-to-Treat tumors?